To help hospitals and health systems meet demand during the current surge in respiratory illnesses for fever-reducing products to treat pediatric patients and adults unable to swallow solid oral dosage forms, the Food and Drug Administration Friday released guidance for outsourcing facilities compounding certain ibuprofen oral suspension products.

“Although FDA is monitoring the global pharmaceutical supply chain and working, within its authorities, with manufacturers of approved ibuprofen oral suspension products, to bolster supply, temporary flexibility is needed to help ensure that treatment options are available to hospitals and health systems during this period of increased demand,” the guidance states. 

Related News Articles

Headline
President Biden will issue a determination that gives the Department of Health and Human Services broader authority to invest in domestic manufacturing of…
Headline
In the wake of tornado damage last week to a large Pfizer sterile injectables plant in North Carolina, the Food and Drug Administration July 28 posted a list…
Headline
The Association for Health Care Resource & Materials Management annual conference August 6-9 in Orlando offers supply chain leaders a chance to collaborate…
Blog
The upcoming AHRMM annual conference, which will be held August 6-9 in Orlando, is an opportunity for supply chain leaders to collaborate, learn best practices…
Perspective
Hospitals and health systems are cornerstones of communities across our nation. The more than 6 million people who work there provide care, compassion and…
Headline
The Department of Health and Human Services’ Office on Trafficking in Persons last week issued a request for information on forced labor in health care supply…